The purpose of this study is to collect long-term safety, tolerability, effectiveness and health outcomes data in eligible subjects who have participated in a Novartis ofatumumab clinical MS study.

Vaccination sub-study The purpose of this research sub-study is to find out the effects of ofatumumab on the development of antibody responses to selected vaccines and keyhole limpet hemocyanin (KLH) neo-antigen in subjects with relapsing multiple sclerosis (RMS).

COVID-19 sub-study:

The purpose of this research sub-study is to explore the immune response following Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) vaccination in a subset of subjects on long-term ofatumumab 20 mg sc. Note: Novartis is not supplying the SARS-CoV-2 vaccine.

Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS

Westerville, OH

Northbrook, IL

Office of Clinical Trials

Pensacola, FL

Ormond Beach, FL

Wellesley, MA

Clearwater, FL

Tampa, FL

Bradenton, FL

Houston, TX

Port Charlotte, FL

Colorado Springs, CO

Hollywood, FL

Boulder, CO

Novartis

Find clinical trials for Multiple Sclerosis (MS) in Indianapolis, IN

Related conditions:

Multiple Sclerosis (MS) trials near Indianapolis, IN, USA:

Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS (ALITHIOS)